Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 11 of 11 entries
Sorted by: Best Match Show Resources per page
Epidemiology of the diabetic heart.

Coronary artery disease

Tziakas DN, Chalikias GK, Kaski JC.
PMID: 16340402
Coron Artery Dis. 2005 Nov;16:S3-S10. doi: 10.1097/00019501-200511001-00002.

Diabetes mellitus is a worldwide epidemic. Cardiovascular disease remains the major cause of morbidity and mortality in people with diabetes. Studies have suggested that increased risk of cardiovascular disease is not restricted to type II or type I diabetes...

Cite
Tziakas DN, Chalikias GK, Kaski JC. Epidemiology of the diabetic heart. Coron Artery Dis. 2005;16:S3-S10doi: 10.1097/00019501-200511001-00002.
Tziakas, D. N., Chalikias, G. K., & Kaski, J. C. (2005). Epidemiology of the diabetic heart. Coronary artery disease, 16S3-S10. https://doi.org/10.1097/00019501-200511001-00002
Tziakas, Dimitrios N, et al. "Epidemiology of the diabetic heart." Coronary artery disease vol. 16 (2005): S3-S10. doi: https://doi.org/10.1097/00019501-200511001-00002
Tziakas DN, Chalikias GK, Kaski JC. Epidemiology of the diabetic heart. Coron Artery Dis. 2005 Nov;16:S3-S10. doi: 10.1097/00019501-200511001-00002. PMID: 16340402.
Copy Download .nbib Format: NLM
[Metabolic syndrome, diabetes mellitus and vulnerability: a syndemic approach of chronic diseases].

Revue medicale suisse

Ruiz J, Egli M.
PMID: 21155296
Rev Med Suisse. 2010 Nov 17;6(271):2205-8.

The pandemic metabolic syndrome is generally attributed to our lifestyle. The current therapeutic strategies are centered on the behavioral changes and pharmacotherapy. A deeply analysis reveals the importance of the socio-cultural determinants with a "dose-responses effect according to the...

Cite
Ruiz J, Egli M. Syndrome métabolique, diabète sucré et vulnérabilité: une approche "syndémique" de la maladie chronique. [Metabolic syndrome, diabetes mellitus and vulnerability: a syndemic approach of chronic diseases]. Rev Med Suisse. 2010;6(271):2205-8
Ruiz, J., & Egli, M. (2010). Syndrome métabolique, diabète sucré et vulnérabilité: une approche "syndémique" de la maladie chronique. [Metabolic syndrome, diabetes mellitus and vulnerability: a syndemic approach of chronic diseases]. Revue medicale suisse, 6(271), 2205-8.
Ruiz, Juan, and Egli, Marc. "Syndrome métabolique, diabète sucré et vulnérabilité: une approche "syndémique" de la maladie chronique." [Metabolic syndrome, diabetes mellitus and vulnerability: a syndemic approach of chronic diseases]. Revue medicale suisse vol. 6,271 (2010): 2205-8.
Ruiz J, Egli M. Syndrome métabolique, diabète sucré et vulnérabilité: une approche "syndémique" de la maladie chronique. [Metabolic syndrome, diabetes mellitus and vulnerability: a syndemic approach of chronic diseases]. Rev Med Suisse. 2010 Nov 17;6(271):2205-8. French. PMID: 21155296.
Copy Download .nbib Format: NLM
Cutaneous manifestations of diabetes mellitus and the metabolic syndrome.

Clinics in dermatology

Karadag AS, Ozlu E, Lavery MJ.
PMID: 29241758
Clin Dermatol. 2018 Jan - Feb;36(1):89-93. doi: 10.1016/j.clindermatol.2017.09.015. Epub 2017 Sep 08.

Metabolic diseases are commonly encountered in the Western world. Cutaneous manifestations are common in metabolic disorders, such as diabetes mellitus (DM) and the metabolic syndrome (MetS), and metabolic diseases may manifest with specific skin findings. MetS and DM share...

Cite
Karadag AS, Ozlu E, Lavery MJ. Cutaneous manifestations of diabetes mellitus and the metabolic syndrome. Clin Dermatol. 2017;36(1):89-93doi: 10.1016/j.clindermatol.2017.09.015.
Karadag, A. S., Ozlu, E., & Lavery, M. J. (2018). Cutaneous manifestations of diabetes mellitus and the metabolic syndrome. Clinics in dermatology, 36(1), 89-93. https://doi.org/10.1016/j.clindermatol.2017.09.015
Karadag, Ayse Serap, et al. "Cutaneous manifestations of diabetes mellitus and the metabolic syndrome." Clinics in dermatology vol. 36,1 (2018): 89-93. doi: https://doi.org/10.1016/j.clindermatol.2017.09.015
Karadag AS, Ozlu E, Lavery MJ. Cutaneous manifestations of diabetes mellitus and the metabolic syndrome. Clin Dermatol. 2018 Jan - Feb;36(1):89-93. doi: 10.1016/j.clindermatol.2017.09.015. Epub 2017 Sep 08. PMID: 29241758.
Copy Download .nbib Format: NLM
[Metabolic syndrome and its complexity].

Revue medicale de la Suisse romande

Ruiz J.
PMID: 12094496
Rev Med Suisse Romande. 2002 May;122(5):213-6.

Changes in human lifestyle over the last century have produced a dramatic increase of diabetes and obesity worldwide. These two chronic diseases are components of the metabolic syndrome, which is associated with high incidence of cardiovascular disease. Genetic and...

Cite
Ruiz J. Le syndrome métabolique et sa complexité. [Metabolic syndrome and its complexity]. Rev Med Suisse Romande. 2002;122(5):213-6
Ruiz, J. (2002). Le syndrome métabolique et sa complexité. [Metabolic syndrome and its complexity]. Revue medicale de la Suisse romande, 122(5), 213-6.
Ruiz, Juan. "Le syndrome métabolique et sa complexité." [Metabolic syndrome and its complexity]. Revue medicale de la Suisse romande vol. 122,5 (2002): 213-6.
Ruiz J. Le syndrome métabolique et sa complexité. [Metabolic syndrome and its complexity]. Rev Med Suisse Romande. 2002 May;122(5):213-6. French. PMID: 12094496.
Copy Download .nbib Format: NLM
[Total care for patients with metabolic syndrome].

Nihon rinsho. Japanese journal of clinical medicine

Takata N, Katayama S.
PMID: 15206158
Nihon Rinsho. 2004 Jun;62(6):1164-9.

Insulin resistance plays an important role in the pathogenesis of metabolic syndrome and hence an improvement of insulin resistance is important in the treatment of metabolic syndrome. Oral hypoglycemic agents such as thiazolidinediones and biguanides improve glycemic control by...

Cite
Takata N, Katayama S. [Total care for patients with metabolic syndrome]. Nihon Rinsho. 2004;62(6):1164-9
Takata, N., & Katayama, S. (2004). [Total care for patients with metabolic syndrome]. Nihon rinsho. Japanese journal of clinical medicine, 62(6), 1164-9.
Takata, Nobuki, and Katayama, Shigehiro. "[Total care for patients with metabolic syndrome]." Nihon rinsho. Japanese journal of clinical medicine vol. 62,6 (2004): 1164-9.
Takata N, Katayama S. [Total care for patients with metabolic syndrome]. Nihon Rinsho. 2004 Jun;62(6):1164-9. Japanese. PMID: 15206158.
Copy Download .nbib Format: NLM
PPAR delta as a therapeutic target in metabolic disease.

FEBS letters

Reilly SM, Lee CH.
PMID: 18036566
FEBS Lett. 2008 Jan 09;582(1):26-31. doi: 10.1016/j.febslet.2007.11.040. Epub 2007 Nov 26.

PPAR delta is the only member in the PPAR subfamily of nuclear receptors that is not a target of current drugs. Animal studies demonstrate PPAR delta activation exerts many favorable effects, including reducing weight gain, increasing skeletal muscle metabolic...

Cite
Reilly SM, Lee CH. PPAR delta as a therapeutic target in metabolic disease. FEBS Lett. 2007;582(1):26-31doi: 10.1016/j.febslet.2007.11.040.
Reilly, S. M., & Lee, C. H. (2008). PPAR delta as a therapeutic target in metabolic disease. FEBS letters, 582(1), 26-31. https://doi.org/10.1016/j.febslet.2007.11.040
Reilly, Shannon M, and Lee, Chih-Hao. "PPAR delta as a therapeutic target in metabolic disease." FEBS letters vol. 582,1 (2008): 26-31. doi: https://doi.org/10.1016/j.febslet.2007.11.040
Reilly SM, Lee CH. PPAR delta as a therapeutic target in metabolic disease. FEBS Lett. 2008 Jan 09;582(1):26-31. doi: 10.1016/j.febslet.2007.11.040. Epub 2007 Nov 26. PMID: 18036566; PMCID: PMC2275052.
Copy Download .nbib Format: NLM
On treating metabolic syndrome: emphasise lifestyle change.

The Lancet. Oncology

Goldstein MR, Mascitelli L, Pezzetta F.
PMID: 20434715
Lancet Oncol. 2010 May;11(5):415. doi: 10.1016/S1470-2045(10)70055-3.

No abstract available.

Cite
Goldstein MR, Mascitelli L, Pezzetta F. On treating metabolic syndrome: emphasise lifestyle change. Lancet Oncol. 2010;11(5):415doi: 10.1016/S1470-2045(10)70055-3.
Goldstein, M. R., Mascitelli, L., & Pezzetta, F. (2010). On treating metabolic syndrome: emphasise lifestyle change. The Lancet. Oncology, 11(5), 415. https://doi.org/10.1016/S1470-2045(10)70055-3
Goldstein, Mark R, et al. "On treating metabolic syndrome: emphasise lifestyle change." The Lancet. Oncology vol. 11,5 (2010): 415. doi: https://doi.org/10.1016/S1470-2045(10)70055-3
Goldstein MR, Mascitelli L, Pezzetta F. On treating metabolic syndrome: emphasise lifestyle change. Lancet Oncol. 2010 May;11(5):415. doi: 10.1016/S1470-2045(10)70055-3. PMID: 20434715.
Copy Download .nbib Format: NLM
Exercise in a bottle: Elucidating how exercise conveys health benefits might lead to new therapeutic options for a range of diseases from cancer to metabolic syndrome.

EMBO reports

Hunter P.
PMID: 26747280
EMBO Rep. 2016 Feb;17(2):136-8. doi: 10.15252/embr.201541835. Epub 2016 Jan 08.

No abstract available.

Cite
Hunter P. Exercise in a bottle: Elucidating how exercise conveys health benefits might lead to new therapeutic options for a range of diseases from cancer to metabolic syndrome. EMBO Rep. 2016;17(2):136-8doi: 10.15252/embr.201541835.
Hunter, P. (2016). Exercise in a bottle: Elucidating how exercise conveys health benefits might lead to new therapeutic options for a range of diseases from cancer to metabolic syndrome. EMBO reports, 17(2), 136-8. https://doi.org/10.15252/embr.201541835
Hunter, Philip. "Exercise in a bottle: Elucidating how exercise conveys health benefits might lead to new therapeutic options for a range of diseases from cancer to metabolic syndrome." EMBO reports vol. 17,2 (2016): 136-8. doi: https://doi.org/10.15252/embr.201541835
Hunter P. Exercise in a bottle: Elucidating how exercise conveys health benefits might lead to new therapeutic options for a range of diseases from cancer to metabolic syndrome. EMBO Rep. 2016 Feb;17(2):136-8. doi: 10.15252/embr.201541835. Epub 2016 Jan 08. PMID: 26747280; PMCID: PMC5290811.
Copy Download .nbib Format: NLM
The metabolic syndrome.

Lancet (London, England)

Eckel RH, Alberti KG, Grundy SM, Zimmet PZ.
PMID: 20109902
Lancet. 2010 Jan 16;375(9710):181-3. doi: 10.1016/S0140-6736(09)61794-3.

No abstract available.

Cite
Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome. Lancet. 2010;375(9710):181-3doi: 10.1016/S0140-6736(09)61794-3.
Eckel, R. H., Alberti, K. G., Grundy, S. M., & Zimmet, P. Z. (2010). The metabolic syndrome. Lancet (London, England), 375(9710), 181-3. https://doi.org/10.1016/S0140-6736(09)61794-3
Eckel, Robert H, et al. "The metabolic syndrome." Lancet (London, England) vol. 375,9710 (2010): 181-3. doi: https://doi.org/10.1016/S0140-6736(09)61794-3
Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2010 Jan 16;375(9710):181-3. doi: 10.1016/S0140-6736(09)61794-3. PMID: 20109902.
Copy Download .nbib Format: NLM
Welcome to new insights into 'Metabolic Syndrome'.

Future medicinal chemistry

Matyus P.
PMID: 21428793
Future Med Chem. 2010 Dec;2(12):1719-20. doi: 10.4155/fmc.10.269.

No abstract available.

Cite
Matyus P. Welcome to new insights into 'Metabolic Syndrome'. Future Med Chem. 2010;2(12):1719-20doi: 10.4155/fmc.10.269.
Matyus, P. (2010). Welcome to new insights into 'Metabolic Syndrome'. Future medicinal chemistry, 2(12), 1719-20. https://doi.org/10.4155/fmc.10.269
Matyus, Peter. "Welcome to new insights into 'Metabolic Syndrome'." Future medicinal chemistry vol. 2,12 (2010): 1719-20. doi: https://doi.org/10.4155/fmc.10.269
Matyus P. Welcome to new insights into 'Metabolic Syndrome'. Future Med Chem. 2010 Dec;2(12):1719-20. doi: 10.4155/fmc.10.269. PMID: 21428793.
Copy Download .nbib Format: NLM
Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension.

Current hypertension reports

Cerezo C, Segura J, Praga M, Ruilope LM.
PMID: 23519746
Curr Hypertens Rep. 2013 Jun;15(3):196-203. doi: 10.1007/s11906-013-0337-4.

Obesity and overweight are nowadays very prevalent worldwide. They are known to be linked with an increased risk of developing cardiovascular comorbidities and mortality. Abdominal obesity is frequently associated with a collection of metabolic disorders that include elevated blood...

Cite
Cerezo C, Segura J, Praga M, et al. Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension. Curr Hypertens Rep. 2013;15(3):196-203doi: 10.1007/s11906-013-0337-4.
Cerezo, C., Segura, J., Praga, M., & Ruilope, L. M. (2013). Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension. Current hypertension reports, 15(3), 196-203. https://doi.org/10.1007/s11906-013-0337-4
Cerezo, César, et al. "Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension." Current hypertension reports vol. 15,3 (2013): 196-203. doi: https://doi.org/10.1007/s11906-013-0337-4
Cerezo C, Segura J, Praga M, Ruilope LM. Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension. Curr Hypertens Rep. 2013 Jun;15(3):196-203. doi: 10.1007/s11906-013-0337-4. PMID: 23519746.
Copy Download .nbib Format: NLM
Showing 1 to 11 of 11 entries